The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $4.17 in the prior trading day, MaxCyte Inc (NASDAQ: MXCT) closed at $4.02, down -3.60%. In other words, the price has decreased by -$3.60 from its previous closing price. On the day, 0.55 million shares were traded.
Ratios:
Our goal is to gain a better understanding of MXCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.22 and its Current Ratio is at 9.81. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on November 29, 2023, initiated with a Buy rating and assigned the stock a target price of $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 27 ’25 when Johnston John Joseph sold 3,000 shares for $4.64 per share. The transaction valued at 13,935 led to the insider holds 141,950 shares of the business.
Sandoval David I. sold 4,466 shares of MXCT for $20,272 on Jan 13 ’25. The GENERAL COUNSEL now owns 41,447 shares after completing the transaction at $4.54 per share. On Dec 26 ’24, another insider, Johnston John Joseph, who serves as the Director of the company, sold 3,000 shares for $4.01 each. As a result, the insider received 12,021 and left with 141,950 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.30 while its Price-to-Book (P/B) ratio in mrq is 1.98.
Stock Price History:
Over the past 52 weeks, MXCT has reached a high of $5.26, while it has fallen to a 52-week low of $3.16. The 50-Day Moving Average of the stock is -7.88%, while the 200-Day Moving Average is calculated to be -3.77%.
Shares Statistics:
A total of 105.30M shares are outstanding, with a floating share count of 97.33M. Insiders hold about 7.73% of the company’s shares, while institutions hold 71.41% stake in the company.
Earnings Estimates
A comprehensive evaluation of MaxCyte Inc (MXCT) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.11 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.4 and -$0.43 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.38, with 7.0 analysts recommending between -$0.32 and -$0.47.
Revenue Estimates
6 analysts predict $7.98M in revenue for the current quarter. It ranges from a high estimate of $8.4M to a low estimate of $7.46M. As of the current estimate, MaxCyte Inc’s year-ago sales were $15.67MFor the next quarter, 6 analysts are estimating revenue of $9.52M. There is a high estimate of $10.3M for the next quarter, whereas the lowest estimate is $8.55M.
A total of 8 analysts have provided revenue estimates for MXCT’s current fiscal year. The highest revenue estimate was $39.13M, while the lowest revenue estimate was $37.4M, resulting in an average revenue estimate of $38.18M. In the same quarter a year ago, actual revenue was $41.29MBased on 7 analysts’ estimates, the company’s revenue will be $46.24M in the next fiscal year. The high estimate is $50.42M and the low estimate is $43M.
